Mankind Pharma Limited
ListedMainboardPharmaceuticals & Healthcare · NSE / BSE
Incorporated in 1991, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products across a wide range of acute and chronic therapeutic areas in India, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory. The company offers over 36 brands such as Manforce, Moxikind-CV, Amlokind-AT, Prega News, and Gudcef, supported by one of the largest distribution networks of medical representatives in India, with over 80% of doctors prescribing its formulations. Ranked 4th in domestic sales in FY2022, Mankind Pharma has received numerous awards, including The Best of Bharat Awards 2022, National Awards for Manufacturing Competitiveness Silver Medal 2021, and recognition for Best Design in Healthcare and performance management excellence.
Price Band
₹1026 – ₹1080
Issue Size
₹4326 Cr
Lot Size
13 shares
GMP
₹180
+16.7%
Est. Listing
₹1260
at current GMP
Subscribed
15.32x
overall
Open
25 Apr 2023
Close
27 Apr 2023
Allotment
4 May 2023
Refund
5 May 2023
Demat Credit
6 May 2023
Listing
9 May 2023
Last updated 12 days ago
Live Grey Market Premium
Mankind Pharma Limited GMP Today
Last updated: 19 Oct 2026
Current Premium
₹180+16.7%
Issue Price (Upper)
₹1080
Band: ₹1026 – ₹1080
Estimated Listing Price
₹1260
Upper price + GMP
Lot Size
13 shares
Min investment ₹14,040
Estimated Profit / Lot
₹2,340
13 × ₹180
Mankind Pharma Limited GMP Historical Trend
GMP History
Grey Market Premium trend
+₹180
▲ 0 today
Updated 1 minute ago
Estimated Listing Price
| Date | GMP (₹) | GMP % | Est. Listing |
|---|---|---|---|
| 31 Oct 2026 | +₹180 | 16.7% | ₹1260 |
| 30 Oct 2026 | +₹180 | 16.7% | ₹1260 |
| 29 Oct 2026 | +₹162 | 15.0% | ₹1242 |
GMP is unofficial market data. Not a guarantee of listing performance.
About Mankind Pharma Limited Public Issue & Market Profile
Mankind Pharma Limited is bringing an initial public offering (IPO) in the Pharmaceuticals & Healthcare sector with an aggregate issue size of ₹4,326.36 Crores. The shares are offered at a price band of ₹1026 to ₹1080 per equity share on NSE and BSE. Currently, grey market participants and retail investors are watching the bidding trend, premium movement, and anchor book demand with keen interest.
Public Issue & Pricing Context:
Prospective investors can apply in the retail quota with a minimum of 1 lot comprising 13 shares (approx. ₹14,040 minimum investment). High net-worth individuals (HNI/NII) can bid in the sHNI (₹2 Lakh to ₹10 Lakh) or bHNI (above ₹10 Lakh) categories for enhanced quota allocation.
Basis of Allotment & Listing Timeline:
Allotment reconciliation will be managed by KFin Technologies Limited. Eligible allottees will receive credit of equity shares into their Demat accounts by 2023-05-06, while un-allotted funds or UPI block mandates will be released on 2023-05-05.
Frequently Asked Questions
What is Mankind Pharma Limited IPO GMP today?
The latest grey market premium for Mankind Pharma Limited IPO is ₹180, which indicates an expected listing price of ₹1260.
What does Kostak Rate and Sauda mean in IPO GMP?
Kostak rate is the profit amount an investor earns by selling their entire IPO application in the grey market before allotment is finalized.
Is Grey Market Premium officially recognized?
No. GMP is an unofficial indicator discovered between dealers outside of SEBI-regulated exchanges. Actual listing price is determined by demand-supply discovery on NSE/BSE during the pre-open auction.